Alzheimer’s

Clinical Setback in Alzheimer’s Research Pharmaceutical giant Roche announced on Monday that its experimental Alzheimer’s drug, gantenerumab, failed to meet its primary objectives in two large-scale Phase 3 clinical trials. The study, which tracked patients at high risk of memory loss and those in early stages of the disease, revealed that the treatment did not…